Stock Events

Stock Events

MAIA Biotechnology 

$1.4
0
+$0.1+7.69% Today

Statistics

Day High
1.4
Day Low
1.3
52W High
-
52W Low
-
Volume
1,141
Avg. Volume
-
Mkt Cap
51.84M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4MayExpected
Q3 2025
Next
-0.27
-0.24
-0.21
-0.18
Expected EPS
-0.18
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-46.51MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MAIA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a leading pharmaceutical company that competes with MAIA in the oncology sector, particularly in developing cancer treatments.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is involved in the discovery, development, and delivery of cancer therapies, directly competing with MAIA's focus on innovative oncology treatments.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad portfolio of oncology drugs and invests heavily in cancer research, making it a competitor in the cancer treatment market alongside MAIA.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is a global healthcare company that competes with MAIA in developing advanced therapies for various cancers.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is known for its strong presence in the oncology and hematology market, competing with MAIA in cancer treatment research and development.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. focuses on human therapeutics, including oncology/hematology, which puts it in direct competition with MAIA Biotechnology's cancer treatment innovations.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG operates in the pharmaceuticals and diagnostics sectors, with a significant focus on oncology, making it a competitor in cancer treatment advancements.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a strong pipeline in oncology, competing with MAIA in developing new cancer therapies.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for various diseases, including cancer, competing with MAIA in the oncology market.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions, including cancer, competing with MAIA in the biotechnology and oncology fields.

About

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
Show more...
CEO
ISIN
US5526411021

Listings

XASE
US
MAIA
BOATS
BOATS
MAIA.BOATS

0 Comments

Share your thoughts

FAQ

What is MAIA Biotechnology stock price today?▼
The current price of MAIA.BOATS is $1.4 USD — it has increased by +7.69% in the past 24 hours. Watch MAIA Biotechnology stock price performance more closely on the chart.
What is MAIA Biotechnology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MAIA Biotechnology stocks are traded under the ticker MAIA.BOATS.
What is MAIA Biotechnology market cap?▼
Today MAIA Biotechnology has the market capitalization of 51.84M
When is the next MAIA Biotechnology earnings date?▼
MAIA Biotechnology is going to release the next earnings report on May 04, 2026.
What were MAIA Biotechnology earnings last quarter?▼
MAIA.BOATS earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.19 USD resulting in a -42.11% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is MAIA Biotechnology revenue for the last year?▼
MAIA Biotechnology revenue for the last year amounts to 0 USD.
What is MAIA Biotechnology net income for the last year?▼
MAIA.BOATS net income for the last year is -46.51M USD.
When did MAIA Biotechnology complete a stock split?▼
MAIA Biotechnology has not had any recent stock splits.